Overview
A Study to Evaluate the Efficacy and Safety of AD-218
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2024-10-31
2024-10-31
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to evaluate the efficacy and safety of AD-218Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Addpharma Inc.
Criteria
Inclusion Criteria:- A man or woman over 19 years old.
- Sign on ICF prior to study participation
Exclusion Criteria:
- History of Fibromyalgia, Myopathy etc (CK ≥ 2 X ULN)
- Other exclusions applied